BNT015

/Tag:BNT015
­

Bionaturis unveils the development of six new biotech products

Five of these new drugs point to Animal Health sector that represents a $100 billion global annual worldwide market

According to “Global Animal Healthcare Market Size, Share, Development, Growth and Demand Forecast to 2020” report (by  P&S Market Research) around $29 billion were assigned to pharmaceutical products, feed additives and vaccines in 2014.

The same report forecasts for this segment up to $44 billion by 2020, with a CAGR of 7.0%

The population growth and standard of living, resulting on a higher consumption of milk and meat and an increasing trend of adopting pets are some of the main robust drivers for the growth of the Animal Health market, which has nowadays a booming demand on both biological products and compounds devoted to reduce the use of traditional antibiotics

Broadening its portfolio Bionaturis Group strengthens its position as a reference partner to develop biological products for animal health from livestock to pets, having presence in the main markets at geographic, species and diseases level

 

Jerez de la Frontera, October 6th 2015. Bionaturis Group (ticker BNT) has recently unveiled up to six new biotech developments broadening its products portfolio, now accounting for more than twenty compounds in different developing stages for both human and animal health.

Five of these new products are devoted to veterinarian sector, pointing to several high-relevance diseases in livestock and pets, such as atopic dermatitis, osteoarthritis (or arthrosis) and different types of cancer, enhancing the Group position as a benchmark partner in the development of biological products for animal health.

The new unveiled products are:

Lead

Description

Indication

Specie

Stage

BNT014
Tailored universal VLP-vaccine
Prevention of common cold (rhinovirus)
Humans
Proof of concept in vivo

BNT015
Recombinant VPL Vaccine
Viral infection
Swine
Proof of concept in vivo

BNT018
Recombinant VPL Vaccine
Rabbit Hemorrhagic Fever
Rabits
Proof of concept in vivo

BNT020
Feline recombinant interferon omega (bio-better)
Antiviral, antiproliferative, immunomodulatory
Dogs and cats
Proof of […]

October 6th, 2015|Blog english, Press Releases|Comments Off on Bionaturis unveils the development of six new biotech products

Uso de cookies

Este sitio web utiliza cookies para que usted tenga la mejor experiencia de usuario. Si continúa navegando está dando su consentimiento para la aceptación de las mencionadas cookies y la aceptación de nuestra política de cookies, pinche el enlace para mayor información.

CERRAR